Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02584933 · ClinicalTrials.gov registry record · Phase 4
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
A Phase 4 study of ALK Positive Malignancies, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 4
- Development phase
- 233
- Enrollment target
- 20
- Study locations
NCT02584933: Active Phase 4 study of ALK Positive Malignancies, sponsored by Novartis Pharmaceuticals.
NCT02584933 is a Phase 4 study of ALK Positive Malignancies that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 233 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02584933, a Phase 4 study of ALK Positive Malignancies, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 233 participants
- Enrollment target
- 20
- Study locations
Study Summary
The rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a Novartis-sponsored study and in the opinion of the investigator, would benefit from continued treatment with ceritinib.
Primary Outcome
To collect safety data: adverse events and serious adverse events
Conditions Studied
Interventions
- DRUG ceritinib
Study Locations (20)
Other
- Novartis Investigative Site - Auckland
- Novartis Investigative Site - Leuven
- Novartis Investigative Site - Sofia
- Novartis Investigative Site - Beijing
- Novartis Investigative Site - Guangzhou
- Novartis Investigative Site - Montería
- Novartis Investigative Site - Brno
São Paulo
- Novartis Investigative Site - Barretos
- Novartis Investigative Site - São Paulo
Guangdong
- Novartis Investigative Site - Guangzhou
- Novartis Investigative Site - Guangzhou
Arkansas
- Highlands Oncology Group - Fayetteville
California
- Loma Linda University - Loma Linda
Colorado
- University of Colorado Cancer Center - Aurora
Maryland
- Maryland Oncology Hematology P A - Rockville
New Jersey
- Essex Oncology of North Jersey PA - Belleville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 233 participants |
| Start Date | 2015-12-11 |
| Est. Completion | 2027-06-09 |
| Phase | Phase 4 |
What the registry record for NCT02584933 still lists
NCT02584933 is an interventional study that assigns participants to a tested intervention. The registered 233 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (55% lower).
The record links to 1 condition, with ALK Positive Malignancies appearing as the primary indexed condition, and to 1 intervention - of which ceritinib is the first listed.
NCT02584933 names 20 study sites across 12 states, led by Other, São Paulo, Guangdong.
Frequently Asked Questions
What is clinical trial NCT02584933 about?
NCT02584933 is a clinical study titled "Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study". The rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a Novartis-sponsored study and in the opinion of the investigator, would benefit from continued treatment with ceritinib.
What is the current status of trial NCT02584933?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 233 participants. The study started on 2015-12-11. Estimated completion is 2027-06-09.
What conditions does trial NCT02584933 study?
This clinical trial studies the following conditions: ALK Positive Malignancies.
What interventions are being tested in trial NCT02584933?
The interventions under investigation include: ceritinib (DRUG).
Who is sponsoring clinical trial NCT02584933?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02584933 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Maryland, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02584933's enrollment target sits among peer trials
233 369th of 2000 higher than 1,632 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06993844 · 233 participants · Phase 1
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- NCT07141706 · 233 participants · Phase 1
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
- NCT04942717 · 234 participants · NA
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
- NCT05208671 · 234 participants · NA
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI